Literature DB >> 9585711

Social phobia subtypes in the National Comorbidity Survey.

R C Kessler1, M B Stein, P Berglund.   

Abstract

OBJECTIVE: This article presents epidemiologic data on the distinction between social phobia characterized by pure speaking fears and that characterized by other social fears.
METHOD: The data come from the National Comorbidity Survey (N = 8,098). Social phobia was assessed with a revised version of the Composite International Diagnostic Interview.
RESULTS: Latent class analysis showed that the brief set of social fears assessed in the survey can be disaggregated into a class characterized largely by speaking fears and a second class characterized by a broader range of social fears. One-third of the people with lifetime social phobia exclusively reported speaking fears, while the other two-thirds also had at least one of the other social fears assessed. The vast majority of the latter had multiple social fears including, in most cases, both performance and interactional fears. The two subtypes were similar in age at onset distribution, family history, and certain sociodemographic correlates. However, the social phobia characterized by pure speaking fears was less persistent, less impairing, and less highly comorbid with other DSM-III-R disorders than was social phobia characterized by other social fears.
CONCLUSIONS: Further general population research assessing more performance and interaction fears is needed to determine whether social phobia subtypes can be refined and whether the subtypes are better conceptualized as distinct disorders. In the meantime, people who have social phobia with multiple fears, some of which are nonspeaking fears, appear to have the most impairment and should be the main focus of prevention and intervention efforts.

Entities:  

Mesh:

Year:  1998        PMID: 9585711     DOI: 10.1176/ajp.155.5.613

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  45 in total

Review 1.  Unmasking social anxiety disorder.

Authors:  M B Stein; J M Gorman
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Social phobia: further evidence of dimensional structure.

Authors:  Erica Crome; Andrew Baillie; Tim Slade; Ayelet Meron Ruscio
Journal:  Aust N Z J Psychiatry       Date:  2010-11       Impact factor: 5.744

Review 3.  Social anxiety disorder : current treatment recommendations.

Authors:  Jacqueline E Muller; Liezl Koen; Soraya Seedat; Dan J Stein
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Validation of the diagnoses of panic disorder and phobic disorders in the US National Comorbidity Survey Replication Adolescent (NCS-A) supplement.

Authors:  Jennifer Greif Green; Shelli Avenevoli; Matthew Finkelman; Michael J Gruber; Ronald C Kessler; Kathleen R Merikangas; Nancy A Sampson; Alan M Zaslavsky
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

5.  Neurofunctional correlates of expressed vocal affect in social phobia.

Authors:  Petri Laukka; Fredrik Ahs; Tomas Furmark; Mats Fredrikson
Journal:  Cogn Affect Behav Neurosci       Date:  2011-09       Impact factor: 3.282

6.  Fearful imagery in social phobia: generalization, comorbidity, and physiological reactivity.

Authors:  Lisa M McTeague; Peter J Lang; Marie-Claude Laplante; Bruce N Cuthbert; Cyd C Strauss; Margaret M Bradley
Journal:  Biol Psychiatry       Date:  2008-11-08       Impact factor: 13.382

7.  Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.

Authors:  Murray B Stein; Mark H Pollack; Alexander Bystritsky; Jeffrey E Kelsey; Richard M Mangano
Journal:  Psychopharmacology (Berl)       Date:  2004-07-16       Impact factor: 4.530

8.  Evaluation of the proposed social anxiety disorder specifier change for DSM-5 in a treatment-seeking sample of anxious youth.

Authors:  Caroline E Kerns; Jonathan S Comer; Donna B Pincus; Stefan G Hofmann
Journal:  Depress Anxiety       Date:  2013-03-14       Impact factor: 6.505

Review 9.  Epidemiologic heterogeneity of common mood and anxiety disorders over the lifecourse in the general population: a systematic review.

Authors:  Arijit Nandi; John R Beard; Sandro Galea
Journal:  BMC Psychiatry       Date:  2009-06-01       Impact factor: 3.630

10.  Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder.

Authors:  C François; S A Montgomery; N Despiegel; S Aballéa; J Roïz; P Auquier
Journal:  Int J Clin Pract       Date:  2008-08-28       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.